SSA
NBSE

Schonfeld Strategic Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-636
Closed – – 3251
2022
Q2 		$0 Buy
+636
New +$14.9K ﹤0.01% 3147
2018
Q3 		– Sell
-32
Closed – – 1063
2018
Q2 		$0 Buy
+32
New +$2.79K ﹤0.01% 1019

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Schonfeld Strategic Advisors's NBSE Position: Q3 2022 in Review

Schonfeld Strategic Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2022, closing a stake of 636 shares.

Schonfeld Strategic Advisors first reported a position in NBSE in Q2 2018 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 44 funds tracked by Wall St. Rank hold NBSE as of Q3 2022.

  • Schonfeld Strategic Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 636 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2022.
  • Schonfeld Strategic Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 44 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.